MIP Diagnostics has received additional cash from Mercia Fund Management, which has backed the Leicester spinout since 2015.
MIP Diagnostics, a UK-based polymer antibodies developer based on University of Leicester research, received £300,000 ($390,000) of follow-on funding from enterprise investment scheme Mercia Fund Management on Wednesday.
Founded in 2015, the spinout produces molecular imprinted polymers (MIPs) used in the diagnostic, pharmaceutical, biotechnology and chemical research sectors. MIPs are able to mimic biological antibodies but are more stable and non-biodegradable.
MIPs are also more cost-effective, can be made in days rather than months and have a longer shelf-life.
The…
